癌症治疗：新治疗技术的报销
Cancer therapy: reimbursement of new therapeutic technologies.
作者信息
Williams H M
机构信息
Aetna Life and Casualty Company, Employee Benefits Division, Middletown, Connecticut.
出版信息
Yale J Biol Med. 1992 Mar-Apr;65(2):83-97.
New drugs and technologies for cancer treatment are being developed at a rate that has created a reimbursement crisis. This article discusses third-party concerns about this problem and describes generic criteria that have proven to be useful in assessing any new technology. It is equally important to discontinue funding of ineffective and obsolete therapies as it is to devise a strategy for identifying and encouraging the development of new therapy that will be both clinically useful and cost-effective. Examples are provided to show that these are not necessarily mutually exclusive goals. Off-label application of standard therapy as well as the funding of new cancer therapy are considered. High-dose chemotherapy with autologous stem-cell support for treatment of a variety of neoplasms has become a major reimbursement challenge. Other technologies such as autolymphocyte therapy and use of colony-stimulating factors are considered in detail. Finally, a process for deciding how to fund new cancer therapy is described.
癌症治疗的新药和新技术正以前所未有的速度研发，这引发了报销危机。本文讨论了第三方对此问题的担忧，并描述了已被证明在评估任何新技术时都有用的通用标准。停止对无效和过时疗法的资助，与制定一项识别和鼓励开发既具有临床实用性又具有成本效益的新疗法的策略同样重要。文中给出了例子来说明这些目标并非必然相互排斥。还考虑了标准疗法的非标签应用以及新癌症疗法的资金投入。大剂量化疗联合自体干细胞支持治疗多种肿瘤已成为报销的一大挑战。文中还详细讨论了其他技术，如自体淋巴细胞疗法和集落刺激因子的使用。最后，描述了一个决定如何为新癌症疗法提供资金的流程。
Zotero 插件